The clinical features and outcomes of Turkish patients with IgG4-related disease:a single-center experience

Background/aim: Since the majority of the IgG4-related disease (IgG4-RD) patients in the literature are from the Far East and the United States, there is a lack of large series from other parts of the world. We aimed to identify the clinical characteristics and outcome of Turkish IgG4-RD patients from a tertiary center. Materials and methods: Fifty-two patients classified as having definite IgG4-RD according to comprehensive diagnostic criteria were included in the study. Patients not fulfilling the definite criteria due to lack of pathologic specimen and/or serum IgG4 levels were excluded (n = 47). Clinical, laboratory, and histopathological features and treatment approaches were analyzed. Results: Median age at diagnosis was 51.1 years and sex predominance was not observed (male/female: 26/26). Median follow-up duration was 18 (IQR 25 75: 8 35) months. Retroperitoneal fibrosis was the most frequent presentation. Twenty-four (46.1%) patients had localized involvement. Corticosteroids were the mainstay of treatment (92.5%). Rituximab had been used for cases resistant to previous treatment or with relapses in 19 (47.5%) patients. A complete response was achieved in 52.5% and partial response (

PDF

___

1. Stone JH, Zen Y, Deshpande V. IgG4 related disease. N Engl J Med 2012; 366: 539-551.
2. Brito-Zerón P, Ramos-Casals M, Bosch X, Stone JH. The clinical spectrum of IgG4-related disease. Autoimmun Rev 2014; 13: 1203-1210.
3. Mayo, Sekiguchi H, Horie R, Kanai M. IgG4-related disease: retrospective analysis of one hundred sixty-six patients. Arthritis Rheumatol 2016; 68: 2290-2299.
4. Wallace ZS, Deshpande V, Mattoo H, Mahajan VS, Kulikova M, Pillai S, Stone JH. IgG4-related disease: clinical and laboratory features in 125 patients. Arthritis Rheumatol 2015; 67: 2466- 2475.
5. Soliotis F, Mavragani CP, Plastiras SC, Rontogianni D, Skopouli FN, Moutsopoulos HM. IgG4-related disease: a rheumatologists perspective. Clin Exp Rheumatol 2014; 32: 724-727.
6. Szántó A, Nagy G, Molnár CS, Griger Z, Tarr T, Zeher ME. Description of patients with IgG4-related disease from a Hungarian centre. Scand J Rheumatol 2014; 43: 334-337.
7. Huggett MT, Culver EL, Kumar M, Hurst JM, Rodriguez-Justo M, Chapman MH, Johnson GJ, Pereira SP, Chapman RW, Webster GJ et al. Type 1 autoimmune pancreatitis and IgG4- related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort. Am J Gastroenterol 2014; 109: 1675-1683.
8. Agaimy A, Weyand M, Strecker T. Inflammatory thoracic aortic aneurysm (lymphoplasmacytic thoracic aortitis): a 13-year-experience at a German heart center with emphasis on possible role of IgG4. Int J Clin Exp Pathol 2013; 6: 1713-1722.
9. Ebbo M, Daniel L, Pavic M, Sève P, Hamidou M, Andres E, Burtey S, Chiche L, Serratrice J, Longy-Boursier M et al. IgG4- related systemic disease: features and treatment response in a French cohort: results of a multicenter registry. Medicine (Baltimore) 2012; 91: 49-56.
10. Fernández-Codina A, Martínez-Valle F, Pinilla B, López C, DeTorres I, Solans-Laqué R, Fraile-Rodríguez G, CasanovasMartínez A, López-Dupla M, Robles-Marhuenda Á et al. IgG4- related disease: results from a multicenter Spanish registry. Medicine (Baltimore) 2015; 94: e1275.
11. Campochiaro C, Ramirez GA, Bozzolo EP, Lanzillotta M, Berti A, Baldissera E, Dagna L, Praderio L, Scotti R, Tresoldi M et al. IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients. Scand J Rheumatol 2016; 45: 135- 145.
12. Martínez-Valle F, Fernández-Codina A, Pinal-Fernández I, Orozco-Gálvez O, Vilardell-Tarrés M. IgG4-related disease: evidence from six recent cohorts. Autoimmun Rev 2017; 16: 168-172.
13. Carruthers MN, Khosroshahi A, Augustin T, Deshpande V, Stone JH. The diagnostic utility of serum IgG4 concentrations in IgG4 related disease. Ann Rheum Dis 2015; 74: 14-18.
14. Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Carruthers MN, Chari ST, Della-Torre E, Frulloni L, Goto H et al. International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease. Arthritis Rheumatol 2015; 67: 1688-1699.
15. Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, Matsui S, Yoshino T, Nakamura S, Kawa S et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 2012; 22: 21-30.
16. Mavrogeni S, Markousis-Mavrogenis G, Kolovou G. IgG4-related cardiovascular disease. The emerging role of cardiovascular imaging. Eur J Radiol 2017; 86: 169-175.
17. Jones EA, Alexander MK. Idiopathic retroperitoneal fibrosis associated with an arteritis. Ann Rheum Dis 1966; 25: 356-360.
18. Sakomoto A, Nagai R, Saito K, Imai Y, Takahashi M, Hosoya Y, Takeda N, Hirano K, Koike K, Enomoto Y et al. Idiopathic retroperitoneal fibrosis, inflammatory aortic aneurysm, and inflammatory pericarditisRetrospective analysis of 11 case histories. J Cardiol 2012; 59: 139-146.
19. Inoue D, Zen Y, Abo H, Gabata T, Demachi H, Yoshikawa J, Miyayama S, Nakanuma Y, Matsui O. Immunoglobulin G4- related periaortitis and periarteritis: CT findings of 17 patients. Radiology, 2011; 261: 625-633.
20. Tanigawa J, Daimon M, Murai M, Katsumata T, Tsuji M, Ishizaka N. Immunoglobulin G4-related coronary periarteritis in a patient presenting with myocardial ischemia. Hum Pathol 2012; 43: 1131-1134.
21. Martínez-de-Alegría A, Baleato-González S, García-Figueiras R, Bermúdez-Naveira A, Abdulkader-Nallib I, Díaz-Peromingo JA, Villalba-Martín C. IgG4-related disease from head to toe. Radiographics 2015; 35: 2007-2025.
22. Kurt E, Metintas S, Basyigit I, Bulut I, Coskun E, Dabak S, Deveci F, Fidan F, Kaynar H, Kunt Uzaslan E et al. Prevalence and Risk Factors of Allergies in Turkey (PARFAIT): results of a multicentre cross-sectional study in adults. Eur Respir J 2009; 33: 724-733.
23. Inoue D, Yoshida K, Yoneda N, Ozaki K, Matsubara T, Nagai K, Okumura K, Toshima F, Toyama J, Minami T et al. IgG4- related disease: dataset of 235 consecutive patients. Medicine (Baltimore) 2015; 94: e680.
24. Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, Klöppel G, Heathcote JG, Khosroshahi A, Ferry JA et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol 2012; 25: 1181-1192.
25. Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, Deshpande V, Smyrk TC, Chari S, Stone JH. Rituximab for IgG4-related disease: a prospective, openlabel trial. Ann Rheum Dis 2015; 74: 1171-1177.
26. Carruthers MN, Stone JH, Despande V, Khoroshahi A. Development of an IgG4-RD Responder Index. Int J Rheumatol 2012; 2012: 259408.